Foundation Medicine has launched FoundationOne, its targeted sequencing-based cancer test, which screens for mutations in 200 cancer-related genes. The test is offered out of the company's CLIA certified laboratory on the Illumina HiSeq 2000 with a turnaround time of 21 days. The test must be ordered by a physician and is used to match genomic alterations with a targeted therapy or clinical trial.
Omixon has launched Target, software analysis for targeted sequencing data designed for diagnostic labs looking to adopt next-gen sequencing. According to the company, Target uses profiles with parameters set up for the particular gene target, to ensure precision for diverse assays, such as oncogenes or immune-system genes.